0001193125-21-082774.txt : 20210415 0001193125-21-082774.hdr.sgml : 20210415 20210316160401 ACCESSION NUMBER: 0001193125-21-082774 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20210316 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Connect Biopharma Holdings Ltd CENTRAL INDEX KEY: 0001835268 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: SCIENCE & TECH PARK, EAST R&D BLDG, 3 FL STREET 2: EAST R&D BUILDING, 3RD FLOOR CITY: 6 BEIJING WEST ROAD, TAICANG STATE: F4 ZIP: 215400 BUSINESS PHONE: 86 512 5357 7866 MAIL ADDRESS: STREET 1: SCIENCE & TECH PARK, EAST R&D BLDG, 3 FL STREET 2: EAST R&D BUILDING, 3RD FLOOR CITY: 6 BEIJING WEST ROAD, TAICANG STATE: F4 ZIP: 215400 CORRESP 1 filename1.htm CORRESP

Jefferies LLC

520 Madison Avenue

New York, New York 10022

SVB Leerink LLC

255 California Street, 12th Floor

San Francisco, California 94111

Piper Sandler & Co.

800 Nicollet Mall

Minneapolis, Minnesota 55402

China International Capital Corporation Hong Kong Securities Limited

29th Floor, One International Finance Centre

1 Harbour View Street, Central

Hong Kong

March 16, 2021

VIA EDGAR

Office of Life Sciences

Division of Corporation Finance

U.S. Securities and Exchange Commission

100 F Street N.E.

Washington, D.C. 20549

 

Attention:

   

Ada D. Sarmento

Eric Atallah

Vanessa Robertson

Tim Buchmiller

 

Re:

Connect Biopharma Holdings Limited (the “Company”)

  

Registration Statement on Form F-1 (File No. 333-253631)

  

Registration Statement on Form 8-A (File No. 001-40212)

Ladies and Gentlemen:

We hereby join the Company’s request for acceleration of the above-referenced Registration Statements, requesting effectiveness at 4:00 P.M., Eastern Time on March 18, 2021, or as soon as practicable thereafter.

Pursuant to Rule 460 of the General Rules and Regulations promulgated under the Securities Act of 1933, as amended, we wish to advise you that between March 12, 2021 and the date hereof, approximately 1,050 copies of the preliminary prospectus of the Company dated March 12, 2021 were distributed to prospective underwriters, dealers, institutional investors and others.

We have been advised by the prospective underwriters that they have complied and will continue to comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.

[Signature page follows]

Very truly yours,
JEFFERIES LLC
SVB LEERINK LLC
PIPER SANDLER & CO.

CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED

Acting on behalf of themselves and the several underwriters

JEFFERIES LLC
By:  

/s/ Michael Brinkman

  Name:   Michael Brinkman
  Title:   Managing Director
    Joint US Head of Biopharmaceuticals
SVB LEERINK LLC
By:  

/s/ Stuart Nayman

  Name:   Stuart Nayman
  Title:   Managing Director, Senior Legal Counsel
PIPER SANDLER & CO.
By:  

/s/ Chad Huber

  Name:   Chad Huber
  Title:   Managing Director

CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED

By:  

/s/ Shi Qi

  Name:   Shi Qi
  Title:   Managing Director

[Signature Page to Acceleration Request]